New class of drug destroys, not just inhibits, proteins
Nature - 20-Mar-2019Cancer targeted first, but could clear out age-related proteins in future
Join the club for FREE to access the whole archive and other member benefits.
SVP of Global Research at Amgen and Visiting Associate at California Institute of Technology.
As of May 2017, Raymond Deshaies is Senior Vice President for Discovery Research at Amgen and a Visiting Associate at Caltech. Prior to that, he was a member of the professorial faculty in the Division of Biology and Biological Engineering at Caltech since 1994 and an Investigator of the Howard Hughes Medical Institute since 2000. While at Caltech he founded the Proteome Exploration Laboratory at the Beckman Institute. The Deshaies' Lab investigates the cellular machinery that mediates protein degradation by the ubiquitin-proteasome system, and how this machinery regulates cellular functions.
Visit website: http://www.deshaieslab.com/ray-deshaies.html
See also: Amgen - Biotechnology company that develops and manufactures human therapeutics for various illness and diseases
Details last updated 27-Dec-2019
Cancer targeted first, but could clear out age-related proteins in future